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Background.While the majority of childhood cancer clinical tri-
als are treatment related, additional optional research investigations
may be carried out that do not directly impact on treatment. It is
essential that these studies are conducted ethically and that the ex-
periences of families participating in these studies are as positive as
possible. Methods. A questionnaire study was carried out to inves-
tigate the key factors that influence why families choose to partici-
pate in optional nontherapeutic research studies, the level of under-
standing of the trials involved, and the experiences of participation.
Results. A total of 100 participants from six UK centers were stud-
ied; 77 parents, 10 patients >16 years, and 13 patients aged 8–15
years. Ninety-seven percent of parents and 90% of patients felt that
information provided prior to study consent was of the right length,
with 52% of parents and 65% of patients fully understanding the in-
formation provided. Seventy-four percent of parents participated in
research studies in order to “do something important”, while 74% of
patients participated “to help medical staff”. Encouragingly, <5% of
participants felt that their clinical care would be negatively affected
if they did not participate. Positive aspects of participation included
a perception of increased attention from medical staff. Negative as-
pects included spending longer periods in hospital and the require-
ment for additional blood samples. Ninety-six percent of parents and
87% of patients would participate in future studies. Conclusions.The
study provides an insight into the views of childhood cancer patients
and their parents participating in nontherapeutic clinical research
studies. Overwhelmingly, the findings suggest that participation is
seen as a positive experience. Pediatr Blood Cancer 0000;00:000–
000. C© 2016 The Authors. Pediatric Blood & Cancer, published by Wiley
Periodicals, Inc.
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INTRODUCTION
It is estimated that approximately 60% of children diagnosed
with cancer in the UK participate in clinical trials.[1] The vast
majority of these studies are therapeutic trials, involving the
recruitment of patients to treatment protocols in order to an-
swer specific questions about the drugs being tested and as-
sess how effective they are in the treatment of various different
types of childhood cancer. This has led to significant advances
in the treatment of pediatric malignancies over the past several
decades.[2]
Clinical trials in the modern era have advanced considerably
in terms of their complexity, with numerous “substudies” com-
monly included in the trial design to learn as much as possi-
ble about the treatments being investigated. Although interven-
tional, commonly involving the collection of additional clinical
samples, these optional studies will not directly impact on the
treatment that they receive. Similarly, in addition to therapeutic
trials that largely define the treatment of the childhood cancer
patient, there are also commonly stand-alone nontherapeutic tri-
als that do not provide treatment to patients, but may facilitate
the generation of knowledge to help advance our understand-
ing of cancer and its treatment. In these scenarios, where the
patients will not benefit directly from their inclusion in the trial
or substudy, ethical questions may be asked about the appropri-
ateness of study participation for children with cancer. Poten-
tial concernsmay include the negative impact of being separated
from parents, concerns over the frequency and volume of clini-
cal samples being collected for research purposes, in addition to
discomfort and inconvenience brought about by study involve-
ment. In this respect, our group and others have previously at-
tempted to assess the impact of involvement in clinical studies
involving the collection of blood samples for research purposes
and carried out studies to help reduce the impact of such studies
on the patients involved.[3–6]
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From a scientific perspective, it is fortunate that childhood
cancer patients and their families are frequently willing to
participate in nontherapeutic studies in order to advance our
understanding of cancer and its treatment. However, poor ex-
periences for patients may lead to high rates of study drop out
or low recruitment rates, with a clear negative impact on achieve-
ment of the scientific aims of the study. In considering the
future involvement of patients in clinical trials, it is impor-
tant that we consider the experiences of families who have re-
cently been involved in optional research studies and investigate
the positive and negative experiences of participation. Previous
work in this area includes studies assessing the views of parents
on consent and participation in therapeutic trials for cancer and
other illnesses,[7–11] but very few studies have been published
focusing on the views of both patients and parents of participa-
tion in nontherapeutic trials purely in an oncology setting.
The current study was designed to gain information relating
to the key factors that influence why childhood cancer patients
and their families choose to participate in optional clinical re-
search studies, the level of understanding of the purpose of the
clinical trial, and the pros and cons of participation. By learning
more about the experiences of patients and families participat-
ing in these important studies, researchers and clinical staff can
look to design and conduct trials in such a way as to improve
practices and maximize recruitment to future studies.
METHODS
Study Design
Ethical approval for the study was gained from the Sunder-
landResearch Ethics Committee. The questionnaire was devised
following discussions with the Childhood Cancer Research
Nurses Group (CCRNG), with approaches taken in previously
published studies in this area taken into account to inform the
initial structure of the questionnaire.[9] Two questionnaires
were designed for use in the study, one for parents and patients
>16 years of age and a simplified version for patients aged 8–16
years (see Supplementary Fig. S1). The questionnaire included
predominantly structured questions, designed in conjunction
with the CCRNG, with each question providing an additional
free text option to ensure that participants did not feel limited by
the questionnaire structure. A final questionnaire was approved
following completion of a limited center pilot study involving 20
patients/families. The questionnaire was designed to cover the
following key areas: experiences of the trial recruitment process,
level of understanding of the information provided leading to
study consent, and experiences of the clinical research study
day. Table I provides a summary of key questions included
in the questionnaire, for each of which there were 2–4 graded
answers provided for the participants to select as appropriate.
The content and construct validity of the questionnaire was not
examined.
Recruitment
The eligible study population included childhood cancer
patients and their parents, who had participated in a nonther-
apeutic clinical trial between March, 2010 and May, 2014. It
was stipulated that questionnaires should be completed within a
12-month period following participation in the clinical research
trial. Patients 8 years old were invited to complete an age ap-
TABLE I. Summary of Questions Included in the Study
Questionnaire
Were you happy with the information you were given before you
consented to the study?
Do you think that the parent/patient information sheet was of the
appropriate length?
Do you think that the parent/patient information sheet was
understandable?
How well did you understand the purpose of the trial?
Why did you decide to take part in the study?
Did you feel that making an extra visit to the hospital on the
research study day was a chore?
Did you feel that the length of time the study took was too long?
Did you feel that the number of blood samples taken for the
research study was too many?
In your opinion what were the positive aspects of taking part in
the research study?
In your opinion what were the negative aspects of taking part in
the research study?
Did you feel that you were approached at the right time about
taking part in the research study?
Would you/would you allow your child to take part in future
research studies?
propriate questionnaire themselves, with parents asked to com-
plete the questionnaire for patients <8 years and older patients
who did not wish to complete an independent questionnaire.
Data Collection
Families were approached by the research nurses at a clinic
follow-up visit or during their hospital stay and invited to par-
ticipate. Questionnaires were completed by patients or parents
during the clinic visit, collected by research nurses at the end
of the visit, and sent to Newcastle for data analysis. Informed
consent or assent as appropriate was taken from all study par-
ticipants prior to completion of age-appropriate questionnaires.
Demographic details of the individuals completing the question-
naire were not collected, with the exception of age for patients
completing the questionnaire.
Analysis of Questionnaire Data
The results obtained from the questionnaire were grouped
into four basic areas of interest: “level of understanding of re-
search study aims,”“reasons for participation in clinical research
study,”“impact of study participation,”and “positive and nega-
tive aspects of participation.” In addition to the presentation of
numerical data obtained from the questionnaires, free text com-
ments provided by participants were also considered.
Statistical Analysis
Based on data generated from a pilot study of 20 pa-
tients/families, a total of 100 patients were included in the final
study proposal. Inclusion of 100 patients provided a 90% prob-
ability that the width of the 95% confidence interval for the esti-
mated proportions (comparable data to the responses generated
in the pilot study) would be less than 0.14 (95% confidence inter-
vals of [0.83, 0.97] and [0.03, 0.17]). This was seen as an accept-
able level of precision for the proposed study design. A formal
statistical analysis was not carried out on the results obtained
from the study.
Pediatr Blood Cancer DOI 10.1002/pbc
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Fig. 1. Views of parents (A) and patients (B) on the level of un-
derstanding of the purpose of the nontherapeutic clinical research
study in which they participated.
RESULTS
Patient Accrual
A total of 100 participants were recruited to the study,
77 parents, 10 patients >16 years old, and 13 patients aged
8–15 years. All patients had participated in nontherapeutic
clinical research studies no longer than 12 months prior to
completion of the questionnaire. Patients had participated
in the following nontherapeutic trials or nontherapeutic
substudies within larger clinical trials (ClinicalTrials.gov or
International Standard Randomised Controlled Trial Num-
ber [ISRCTN] identifiers: NCT00897871, NCT00900354,
NCT00939965, NCT01704716, ISRCTN64515327, and IS-
RCTN52616678). All of these studies were comparable in terms
of requesting blood samples at specific times during treatment
for analysis of drug levels (pharmacokinetic studies) in addition
to a blood sample collected pretreatment for pharmacogenetic
analysis. Participants were recruited from six clinical centers
involved in the treatment of children with cancer across the
UK.
Level of Understanding of Research Study Aims
In terms of the information that was provided prior to
participation in a nontherapeutic research study in the form
of parent or patient information sheets, 97% of parents and
90% of patients felt that the information provided was of the
right length, with the remaining participants finding informa-
tion sheets to be too long. Approximately half of the parents
(52%) felt that they fully understood the information provided,
as compared to 65% of patients, with 44% of parents and 30%
of patients understanding the majority of information provided
(Figs. 1A and 1B). It should be noted that for patients re-
cruited to nontherapeutic research studies, information would
have been provided in the form of age-appropriate information
sheets (<8 years old, 8–12 years, 13–15 years, and 16 years).
There was no clear relationship apparent between the level of
understanding stated and the age of the patient studied, al-
though the study size was small and no statistical analysis was
carried out. The vast majority of participants (>99% of both
parents and patients) felt that they were approached about par-
ticipating in the study at the right time.
Reasons for Participation in Clinical Research Study
Table II provides information relating to the reasons for
participating in nontherapeutic clinical research studies. For
the majority of parents, altruistic motives were clearly impor-
TABLE II. Reasons for Participating in Nontherapeutic Clinical
Research Studies
Number of respondents
Reasons for participating Parents (%) Patients (%)
Felt obliged to participate 1 (1.3) 2 (9)
Felt that clinical care would be
affected
2 (2.6) 0 (0)
Feeling of doing something
important
57 (74) 6 (26)
Helping medical staff/giving
something back
41 (53) 17 (74)
Participants were allowed to select as many reasons as they felt were
appropriate.
tant factors, with 74% of parents expressing the “feeling of
doing something important” as a key reason for participating
and 53% of parents feeling that they were “helping medical
staff/giving something back”. These figures compared to values
of 26 and 74%, respectively, for responses obtained frompatients
to the same questions. Encouragingly, less than 5% of respon-
ders felt that their clinical care would be affected if they did not
participate or that they were in any way obliged to participate in
nontherapeutic clinical research studies.
Impact of Study Participation
Answers to questions relating to the impact of being required
to make extra visits to hospital and the length of the study day
were complicated by the fact that some patients and parents were
not required to attend extra visits as they were being treated as
inpatients. In this scenario, the impact of the additional research
study would have largely been in relation to the provision of
additional clinical samples outside of what would have been
collected as part of the routine care of the patient. For those
patients who were required to make additional visits to the
hospital for the research study, 23 of 24 (96%) parents who
responded were happy to make the extra visit as compared to
five of nine (56%) patients. No parents or patients felt that the
research study day was too long.
As patients and parents completing the questionnaire had
participated in clinical pharmacology studies, involving the
collection of sequential blood samples over a defined time
period, a key question was included within the questionnaire
related to the number of blood samples being collected for
research purposes. Interestingly, only 8% of parents and 9%
of patients indicated that too many blood samples were being
taken as part of the research study when this question was
directly asked within the questionnaire.
Positive and Negative Aspects of Participation
Responses to the question of whatwere deemed to be the pos-
itive aspects of taking part in the research study were in align-
ment with the altruistic reasons for participating in the studies,
with 30% of parents and 26% of patients stating this as a posi-
tive aspect of their involvement. Having amember of the clinical
team available to talk to was given as a positive factor by over
half of all respondents (58% of parents and 53% of patients),
with a perceived improvement in clinical care and more timely
Pediatr Blood Cancer DOI 10.1002/pbc
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Fig. 2. Views of parents and patients on the positive (A) and nega-
tive (B) aspects of participating in nontherapeutic clinical research
studies.
administration of medication also highlighted. Factors thatwere
seen as negative aspects of study participation included the
collection of additional blood samples (33% of parents and
24% of patients), the need to spend longer periods in hospital
(19% of parents and 24% of patients), and the requirement to
read and sign additional forms (16% of parents and 18% of pa-
tients). Figures 2A and 2B summarize the positive and negative
aspects of participating in clinical research studies, respectively,
from perspectives of both parent and patient. The vast major-
ity of parents (96%) and patients (87%) stated that they would
participate in future clinical research studies if asked. There was
no indication from the results obtained for any apparent trend
between responses and age of participant, although no formal
statistical analysis was carried out.
DISCUSSION
Bearing in mind the challenges of recruiting patients to pe-
diatric clinical trials, it is clearly important to understand why
parents consent to their children participating in these stud-
ies. While many studies have previously investigated the views
of patients and parents in relation to the provision of consent
and participation in clinical trials across a wide range of disease
types, the majority of these studies related to therapeutic clin-
ical trials involving treatment that may benefit the child being
studied. Indeed, the potential for clinical benefit has previously
been highlighted as a key factor influencing a parent’s decision
to provide consent in several studies both in the UK and other
countries.[7,9,12,13] Even in a phase I trial setting, it has been
widely reported that misconceptions regarding the potential for
therapeutic benefit commonly influence decisions made regard-
ing trial participation.[14,15] The current study was designed to
gain information specifically relating to the factors that influ-
ence why childhood cancer patients and their families choose to
participate in optional nontherapeutic clinical research studies,
the level of understanding of the purpose of the clinical trial in-
volved, and the pros and cons of participation.
When designing clinical trials that will not directly impact on
the treatment of the children participating, it is essential that ap-
propriate information is provided to ensure that the patients and
parents providing consent understand exactly what is involved.
In order to ensure that all children are aware of the reasons for
carrying out the study and what participation entails, informa-
tion sheets are routinely provided for children of varying ages
and intellectual capacity. In this respect, the findings of the cur-
rent study, in terms of level of understanding of the informa-
tion provided, are encouraging. Although no formal testing of
how well participants understood the trials to which they had
been recruited, over half of the parents and two-thirds of pa-
tients felt that they fully understood the information provided,
with over 95% of participants understanding at least the major-
ity of the information included in the study information sheets.
While this was not formally addressed as part of the question-
naire, this would indicate a good understanding of what level
of detail is required to be included in patient information sheets
across a number of research studies to which patients were re-
cruited. This is an area that has been successfully progressed over
a number of years, supported by a trend toward obtaining input
from patient advocacy groups when devising information sheets
for clinical trials.[16,17] Similarly reassuring is the finding that
families were happy with the amount of information provided
and the timing that the research study was discussed with them.
This can often be challenging in terms of not wanting to over-
load patients and parents with information at a difficult time,
particularly in situations where studies are discussed relatively
soon after cancer diagnosis.
As has been reported in previously published studies, a major
factor that influenced study participation relates to the desire to
help generate information that may lead to improved treatments
for future childhood cancer patients. Although many previous
studies have reflected on results obtained from single stud-
ies,[7,9] and therefore may not have been generalizable to other
studies with different risk/benefit profiles, our data have been
generated from patients participating in six different clinical
trials. These studies included both stand-alone clinical research
trials and optional nontherapeutic substudies incorporated in
larger national trials. Despite the relatively high-risk nature of
the cancers involved across these studies, the level of altruism
exhibited is clearly a common factor influencing the level of
participation. Comments provided by parents such as “I was
delighted we could do something vaguely useful and wish we
could have been part of more studies” and “I am pleased to be
able to help as the findings may benefit future parents in my cur-
rent situation” were frequently included in the free text sections
of the questionnaire forms returned. Additional factors cited as
important reasons for participation included a desire to want to
help medical staff conducting clinical research trials and want-
ing to give something back to the clinical team involved in their
treatment. A particularly reassuring finding from the current
study is that very few participants felt any kind of obligation or
Pediatr Blood Cancer DOI 10.1002/pbc
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pressure to participate or that their clinical care may be affected
if they did not consent. This finding underlines the importance
of providing families with information sheets that very clearly
delineate between treatment and research trial procedures.
The findings of the current study should be looked at in the
context of a similar study carried out by theChildren’sOncology
Group (COG) in the United States.[18] The COG study enrolled
36 patients into a study investigating the reasons for participat-
ing in optional pharmacokinetic studies incorporated into phase
1 studies in a childhood cancer setting.While there are a number
of similarities between these two studies, in terms of the patient
population and the requirement for the collection of multiple
blood samples at defined times following drug administration,
some interesting differences are observed in the results obtained.
A factor that was highlighted in the U.S. study as being a con-
cern to the parents and patients studied was the requirement for
additional blood samples that may expose the patient to addi-
tional risks and potential discomfort. Similar findings have been
reported from previous studies, with 42% of patients stipulating
blood procurement as a reason for nonenrollment into a con-
trolled vaccine trial.[19] While this was also a negative aspect of
study participation in the current UK study, with approximately
one-third of participants selecting the collection of extra blood
samples as a negative aspect of study participation, only 8% of
parents and 9% of patients felt that too many blood samples
were taken. Indeed, several parents commented that the number
of samples collected for research purposes was trivial in rela-
tion to the total number collected for routine clinical care. This
raises two important points. First, it is important to note that al-
though patients in the COG study had IV catheters inserted for
blood sampling as part of the pharmacokinetic study, it was stip-
ulated in all of theUK research studies onto which patients were
recruited that all samples were taken from central lines. Indeed,
theU.S. study highlighted a need to validatemethods that permit
samples to be drawn from indwelling central lines, an approach
that has been in place in UK pediatric oncology centers for ethi-
cal reasons for many years. Second, it should be highlighted that
information sheets used for UK research studies in a pediatric
setting frequently include a very clear statement concerning the
maximum volume of blood to be taken and the potential im-
pact on the child participating in the study. Again, this under-
lines the importance of providing clear information for patients
and parents prior to their recruitment into a clinical research
study.
In summary, we can be encouraged that the results from the
current study indicate that we are running well-planned and in-
formative clinical research studies, with patients and parents ex-
pressing positive views on their experiences following participa-
tion. However, we also need to be aware of the limitations of the
study carried out. These include the relatively limited number of
children directly participating in the study and the fact that the
impact of study participation is likely to have been variable de-
pending on whether patients were being treated as inpatients or
outpatients. Similarly, it may have been informative to collate
additional information during the study, including the number
of potential participants who were approached about the study
but chose not to participate and additional patient demograph-
ics including the clinical outcome of the patients on the clinical
trials in which they participated.
Overall, the take-home messages from the current study are
clearly positive and the findings bode well for future trial re-
cruitment, which is essential to make further advances in the
treatment of children with cancer. As one parent of a child
being treated for high-risk neuroblastoma commented, “we
would be more than happy to participate in any future studies
as I believe this is a huge part of finding out more about curing
this disease”. Sharing the findings from this study with parents
and families considering participation in future nontherapeutic
research studies will support the recent provision of excellent
material currently available through the Nuffield council.[20]
Future studies of this nature may benefit from focusing on ob-
taining the views of an increased number of children participat-
ing in nontherapeutic research studies, as opposed to parents,
in addition to addressing some of the limitations of the current
study outlined above.
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